Home › Research › Risk genes beyond APOE
Brain delivery of a neurotrophic peptide derived from secreted amyloid precursor protein APPsα as a therapeutic strategy for Alzheimer's disease
Lena Rehra, Susanne Erdinger, Lelia Wagner, Danny Baltissen, Jennifer Just, Leo König, Eric Mühlberg, Tom Eisenzapf et al.. Journal of Controlled Release, 2025-11-02
Topic: Brain proteins, microglia and lab models
Plain-language summary
Whereas neurotoxic Aβ is derived from amyloid precursor protein (APP) by β- and γ-secretase cleavage, APP processing along the non-amyloidogenic pathway results in the secretion of the large neurotrophic ectodomain APPsα. Together, these data suggest that brain delivery of CTα16 can reverse synaptic damage and enhance functional plasticity of the neuronal network and thus holds therapeutic potential for tauopathies in general and AD in particular. • AAV-iCTα16 mediated expression of the CTα16 peptide rescues spine density in APP/APLP2-deficient cDKO mice. • AAV-iCTα16 restores normal synaptic plasticity in APP/APLP2-deficient cDKO mice. • AAV-iCTα16 restores normal spine density in aged transgenic THY-Tau22 mice, an Alzheimer model with Tau pathology. • Blood brain barrier targeted CTα16 containing liposomes mediate efficient peptide uptake into the brain. • Liposomal delivery of CTα16 peptide restores normal spine density in THYTau22 mice.
What this study adds
Evidence grade: Low
This study used viral and liposomal delivery of a neurotrophic peptide called CTα16 to restore spine density and synaptic plasticity in mouse models of Alzheimer's-like pathology. These are animal results, so it is too early to say whether this approach treats or prevents Alzheimer's disease in people.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rehra, L., Erdinger, S., Wagner, L., Baltissen, D., Just, J., König, L., et al. (2025). Brain delivery of a neurotrophic peptide derived from secreted amyloid precursor protein APPsα as a therapeutic strategy for Alzheimer's disease. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2025.114374
Vancouver
Rehra L, Erdinger S, Wagner L, Baltissen D, Just J, König L, et al. Brain delivery of a neurotrophic peptide derived from secreted amyloid precursor protein APPsα as a therapeutic strategy for Alzheimer's disease. Journal of Controlled Release. 2025. doi:10.1016/j.jconrel.2025.114374. PMID: 41187812.
BibTeX
@article{rehra2025-41187812,
author = {Rehra, Lena and Erdinger, Susanne and Wagner, Lelia and Baltissen, Danny and Just, Jennifer and König, Leo and Mühlberg, Eric and Eisenzapf, Tom and others},
title = {{Brain delivery of a neurotrophic peptide derived from secreted amyloid precursor protein APPsα as a therapeutic strategy for Alzheimer's disease}},
journal = {Journal of Controlled Release},
year = {2025},
doi = {10.1016/j.jconrel.2025.114374},
pmid = {41187812},
url = {https://doi.org/10.1016/j.jconrel.2025.114374}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Whereas neurotoxic Aβ is derived from amyloid precursor protein (APP) by β- and γ-secretase cleavage, APP processing along the non-amyloidogenic pathway results in the secretion of the large neurotrophic ectodomain APPsα.
- Together, these data suggest that brain delivery of CTα16 can reverse synaptic damage and enhance functional plasticity of the neuronal network and thus holds therapeutic potential for tauopathies in general and AD in particular. • AAV-iCTα16 mediated expression of the CTα16 peptide rescues spine density in APP/APLP2-deficient cDKO mice. • AAV-iCTα16 restores normal synaptic plasticity in APP/APLP2-deficient cDKO mice. • AAV-iCTα16 restores normal spine density in aged transgenic THY-Tau22 mice, an Alzheimer model with Tau pathology. • Blood brain barrier targeted CTα16 containing liposomes mediate efficient peptide uptake into the brain. • Liposomal delivery of CTα16 peptide restores normal spine density in THYTau22 mice.
Why it matters
This study used viral and liposomal delivery of a neurotrophic peptide called CTα16 to restore spine density and synaptic plasticity in mouse models of Alzheimer's-like pathology. These are animal results, so it is too early to say whether this approach treats or prevents Alzheimer's disease in people.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Controlled Release) |
| Journal's citation record | 3 / 4 | Journal of Controlled Release: journal h-index 376 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Ulrike Müller: h-index 60 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Heidelberg University: institution h-index 1,344 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41187812) |
| Free to read | 2 / 2 | Free to read |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.jconrel.2025.114374
- PubMed: 41187812
- Original source →
- Free full text: Journal of Controlled Release →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Risk genes beyond APOE from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.